Anne H Cross, Jeffrey M Gelfand, Simon Thebault, Jeffrey L Bennett, H Christian von Büdingen, Briana Cameron, Robert Carruthers, Keith Edwards, Robert Fallis, Rachel Gerstein, Paul S Giacomini, Benjamin Greenberg, David A Hafler, Carolina Ionete, Ulrike W Kaunzner, Lay Kodama, Christopher Lock, Erin E Longbrake, Bruno Musch, Gabriel Pardo, Fredrik Piehl, Martin S Weber, Steven Yuen, Tjalf Ziemssen, Gauruv Bose, Mark S Freedman, Veronica G Anania, Akshaya Ramesh, Ryan C Winger, Xiaoming Jia, Ann Herman, Christopher Harp, Amit Bar-Or
IMPORTANCE: Biomarkers distinguishing nonrelapsing progressive disease biology from relapsing biology in multiple sclerosis (MS) are lacking. Cerebrospinal fluid (CSF) is an accessible fluid that most closely reflects central nervous system biology. OBJECTIVE: To identify CSF biological measures associated with progressive MS pathobiology. DESIGN, SETTING, AND PARTICIPANTS: This cohort study assessed data from 2 prospective MS cohorts: a test cohort provided serial CSF, clinical, and imaging assessments in a multicenter study of patients with relapsing MS (RMS) or primary progressive MS (PPMS) who were initiating anti-CD20 treatment (recruitment: 2016-2018; analysis: 2020-2023)...
March 11, 2024: JAMA Neurology